Immunogenicity and Safety of an MF59^®-Adjuvanted and a Non-Adjuvanted Inactivated Subunit Influenza Vaccine in Adults Affected by Chronic Diseases

Vincenzo Baldo^1*, Tatjana Baldovin¹, Gabriele Angiolelli¹, Pantaleo Nacci², Michele Pellegrini², Derek O’Hagan², Nicola Groth² and Family Medicine Group Of Pianiga³

¹Department of Environmental Medicine and Public Health, Institute of Hygiene, University of Padua, Padua, Italy, E-mail: vincenzo.baldo@unipd.it

²Novartis Vaccines and Diagnostics, Cambridge, USA, E-mail: vincenzo.baldo@unipd.it

³Family Medicine Group of Pianiga, Venice, Italy consisting of the following medical practitioners: C. Barolo, C. Garzotto, I. Matiello and P. Marcato, Italy, E-mail: vincenzo.baldo@unipd.it

^*Corresponding Author: Professor Vincenzo Baldo, Department of Environmental Medicine and Public Health, Institute of Hygiene,, University of Padua, Via Loredan 18, 35131 Padua, Italy, Fax: +39 049 827 5392 Email: